Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F12%3A00103122" target="_blank" >RIV/00843989:_____/12:00103122 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/12:00057975 RIV/00064173:_____/12:N0000001
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1109719" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1109719</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1109719" target="_blank" >10.1056/NEJMoa1109719</a>
Alternative languages
Result language
angličtina
Original language name
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Original language description
BACKGROUND: Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. METHODS: In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patientswho had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. RESULTS: Follow-up in the trial was terminated early after a safety review. After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo (Kaplan-Meier 2-year rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P=0.07). A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
366
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
14
Pages from-to
20-33
UT code for WoS article
000299968800004
EID of the result in the Scopus database
—